Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.51 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | USP8 | P40818 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478916 | 1.00 | AXL (0.53) | AXLSLC20A2SLC20A1SLC40A1CLK1 | |
| SCHEMBL4779284 | 0.92 | AXL (0.51) | AXLSLC20A2SLC20A1SLC40A1CLK1 | |
| SCHEMBL3076728 | 0.91 | AXL (0.47) | AXLSLC20A2SLC20A1SLC40A1CLK1 | |
| SCHEMBL4777395 | 0.87 | AXL (0.54) | AXLSLC40A1CLK1CKS1BSKP2 | |
| SCHEMBL30304828 | 0.87 | SLC40A1 (0.51) | AXLSLC40A1CLK1CKS1BSKP2 | |
| SCHEMBL4727559 | 0.87 | SLC40A1 (0.51) | AXLSLC40A1CLK1CKS1BSKP2 | |
| SCHEMBL3098055 | 0.87 | AXL (0.52) | AXLSLC40A1PGRMEN1GAA | |
| SCHEMBL6374430 | 0.87 | SLC40A1 (0.46) | AXLSLC20A2SLC20A1SLC40A1CLK1 | |
| SCHEMBL30304671 | 0.86 | KEAP1 (0.50) | AXLSLC40A1CKS1BSKP2PGR | |
| SCHEMBL18315257 | 0.86 | KEAP1 (0.50) | AXLSLC40A1CKS1BSKP2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070004784-A1 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-7119112-B2 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1534259-A4 | SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS | ICAGEN INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060094721-A9 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2006-05-04 | — | — | US | disclosed |
| WO-2005113490-A1 | SULFONE-CONTAINING PRODRUGS | ICAGEN, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267032-A1 | Sulfone-containing prodrugs | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1534259-A2 | SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS | Icagen, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106613-A1 | Sulfonamides as potassium channel blockers | ICAGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004016221-A2 | SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS | ICAGEN, INC (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094721-A9 | Sulfonamides as potassium channel blockers | KCNJ2, KCNJ1, KCNJ11 | AXL 4423/4885SLC20A2 137/4885SLC20A1 143/4885 |
| US-20050267032-A1 | Sulfone-containing prodrugs | KCNQ5, KCNE1, KCNH2 | AXL 2493/4885SLC20A2 48/4885SLC20A1 40/4885 |
| US-20040106613-A1 | Sulfonamides as potassium channel blockers | KCNJ2, KCNJ1, KCNJ11 | AXL 4423/4885SLC20A2 137/4885SLC20A1 143/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | AXL 914/4885SLC20A2 2132/4885SLC20A1 2421/4885 |
| US-20070004784-A1 | Sulfonamides as potassium channel blockers | KCNJ2, KCNJ1, KCNJ11 | AXL 4423/4885SLC20A2 137/4885SLC20A1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.